Page Banner
Mayo Clinic Laboratories > Pediatrics > Hematology

Hematology

Comprehensive, data-driven testing

For families with children affected by hematological conditions, including potentially life-threatening hematological cancers, quick access to accurate information about the disease is crucial to identifying the cause and understanding the best treatment approach.

Mayo Clinic Laboratories’ integration with the pediatric hematology practice at Mayo Clinic and ongoing collaboration with hematologists, hematopathologists, genetic counselors, and laboratory testing specialists propels the development of patient-focused evaluations optimized to identify the most common and severe pediatric hematology disorders.

Our comprehensive hematology test menu aids in diagnosis and treatment selection across a wide range of complex hematologic disorders. Our internally developed and validated practice-based algorithms improve patient care, increase efficiency, and reduce costs.

Test menu

Benign hematologic disorders Benign hematologic disorders
Benign hematologic disorders

Because the incidence of distinct red blood cell disorders can vary from common to rare, cases are signed out by board-certified hematopathologists who use comprehensive algorithmic panels to help guide appropriate testing choices and minimize unnecessary assays.

Coagulation disorders Coagulation disorders
Coagulation disorders

Our Special Coagulation Laboratory is led by a multidisciplinary team of physicians. The laboratory offers a broad repertoire of coagulation tests covering a wide spectrum of bleeding, thrombosing, and platelet disorders.

Lymphoid neoplasms Lymphoid neoplasms
Lymphoid neoplasms

Lymphomas are among the most complex diseases to recognize and diagnose because they are pathologically complex, with features that overlap with reactive/inflammatory conditions and other nonhematologic malignancies.

Myeloid neoplasms Myeloid neoplasms
Myeloid neoplasms

The diagnosis and treatment of leukemias can be highly complex, which is why clinicians need a complete picture before proceeding with a course of treatment.

Plasma cell neoplasms Plasma cell neoplasms
Plasma cell neoplasms

Our algorithmic approach ensures that the right tests are ordered at the right time and that healthcare providers get clinically actionable answers for their patients faster. And testing with Mayo Clinic means 24/7 access to our physician and laboratory experts, who are leaders in their fields.

News and updates

The latest

Better Testing for Bleeding Disorders featured image
Better Testing for Bleeding Disorders

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to discuss the Protecting Access to Medicare Act (PAMA) and a recent Cyclospora outbreak making headlines. Later, Dr. Pritt welcomes Juliana Perez Botero, M.D., a Mayo Clinic hematologist, to explore innovative testing approaches for bleeding disorders.

Learn more
T-cell Lymphoma [Test in Focus]

Andrew Feldman, M.D., discusses the different tools and techniques Mayo Clinic Laboratories uses to accurately diagnose and classify T-cell lymphomas to help provide clinicians with the diagnostic answers they need to treat their patients.

Osmotic fragility testing

In this month’s “Hot Topic,” James Hoyer, M.D., discusses the importance of using a control tube during osmotic fragility testing.

<em>IGHV</em> and <em>TP53</em> Sequencing: Clinical Utility in Chronic Lymphocytic Leukemia (CLL)

In this month’s “Hot Topic,” Curtis Hanson, M.D., will discuss the use of laboratory-based prognostic markers in patients with chronic lymphocytic leukemia (CLL). He will also highlight the importance of molecular analyses for IGHV and TP53 sequencing in these patients.

Curtis Hanson, M.D., Discusses Prognostic Markers for Chronic Lymphocytic Leukemia

Curtis Hanson, M.D., discusses the importance of detecting immunoglobulin heavy-chain variable region gene (IGHV) when acquiring prognostic and potentially therapeutic information in chronic lymphocytic leukemia (CLL) patients in CAP TODAY.

New Genetic Test Classifies Lymphomas

The current diagnostic tools in a pathologist’s arsenal sometimes cannot provide a clear distinction between primary mediastinal large B-cell lymphoma (one of the few lymphomas more common in younger women) and diffuse large B-cell lymphoma, the most common type of non-Hodgkin’s lymphoma overall.

Chromogenic Factor VIII and IX Assays: Impact on Diagnosis and Management of Hemophilia

In this month’s “Hot Topic,” Rajiv Pruthi, M.B.B.S., will discuss different types of hemophilia along with their pathologic basis. He will also cover various types of factor assays such as one stage and chromogenic factor assays for diagnosis and their role in management of hemophilia.